Home › All Companies › XERS › Insider Trading

Xeris Biopharma Holdings, Inc. (XERS) — Insider Trading

AI-Powered SEC Filing Analysis

← All XERS filings
Latest Insider Trading Filed: 2026-04-03

Key Insights

  • Insider Beth Hecht sold 16,667 shares of Xeris Biopharma Holdings, Inc. (XERS) on April 1, 2026, at a weighted average price of $5.9914.
  • The sale was made pursuant to a Rule 10b5-1 trading plan, suggesting pre-planned and non-discretionary trading.
  • Hecht remains a significant shareholder, with 1,209,840 shares beneficially owned following the reported transaction.
Sentiment: Neutral Significance: 4/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-04-03. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Xeris Biopharma Holdings, Inc.

Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.